SMAIO creation and launch of the KEOPS plateform, the largest patient database for spinal surgery.
(Software, Machines and Adaptative Implants in Orthopaedics) aims to transform vertebral fusion via breakthrough innovation.
SMAIO offers spine surgeons a complete, integrated by design solution, consisting of software, implantable devices and associated services, to effectively and safely treat spinal pathologies requiring surgery.
Pioneer in the use of clinical data and imaging
for specialists in spine surgery
To achieve this high-level performance,
the i-Kontrol platform was launched in 2021
This holistic concept allows the surgeon to take control of the :
Surgical plan
i-PLAN
Surgical procedure
i-PERFORM
Outcome data
i-CHECK
Education
i-LEARN
Our mission
Improve long-term deformity patient outcomes through precise vertebral realignment.
Our vision
Make spine surgery outcomes more predictable, reproducible, and durable through personalized, integrated by design, realignment solutions empowered by AI and expertise.
Our values
Expertise
Excellence
Dedication
Integrity
SMAIO, from software pure player to complete, integrated by design spine solution
A unique approach combining software planning, data, and implants to realign the spine.
Launch of KEOPS Data Management
First beta version of KBA3D presented to general public during Liverpool Eurospine
CE marking for the Sagittal Balance Analyzer, our spinal realignment planning software.
Spine Society of Australia chooses
KEOPS data management for its registry.
13M€ investment by Otsuka group.
Launch of the Balance Analyzer 3D for more precise surgical realignment planning.
CE marking for our Kheiron spinal fixation system.
FDA approval for our Kheiron spinal fixation system including patient specific K-Rods.
Over 600 surgeries performed in 6 countries.
Annual sales revenue of 1.2 M€.
Over 1,800 surgeries performed to date and launch of K-Rods custom 3D rods.
Annual sales revenue of 2.1 M€.
IPO on Euronext Growth $10M raised.
Over 3,000 surgeries performed in 7 countries.
Annual sales revenue of 2.4 M€.
Over 5 000 surgeries performed to date.
Milestone 1 achieved with
NuVasive (€2.7M) raising
annual sales revenue to 5.4M€.
Sales development with a focus on the United States, the company's primary market.
Annual sales revenue of 5,5 M€.
Sales development focused on the USA.
10M$ annual sales revenue (75% in the USA).
4,5M€ investment.
Open platform partnerships for patient-specific rod distribution with Orthofix & Highridge Medical.
Philippe ROUSSOULY
CEO
Jean-Charles ROUSSOULY
Chief Operations Officer
Renaut FRITSCH
Chief Financial Officer
Aurélie FRETY-ALTARE
Quality Director
Thibaut BASTIEN
Scientific Director
Matthieu VILLE
Chief Commercial Officer